GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » Total Stockholders Equity

Beijing Luzhu Biotechnology Co (HKSE:02480) Total Stockholders Equity : HK$911.36 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co Total Stockholders Equity?

Beijing Luzhu Biotechnology Co's Total Stockholders Equity for the quarter that ended in Dec. 2024 was HK$911.36 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Beijing Luzhu Biotechnology Co's Book Value per Share for the quarter that ended in Dec. 2024 was HK$4.53. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Beijing Luzhu Biotechnology Co's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.08.

Beijing Luzhu Biotechnology Co Total Stockholders Equity Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co Total Stockholders Equity Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Total Stockholders Equity
-715.73 1,046.88 1,116.34 911.36

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Stockholders Equity Get a 7-Day Free Trial 1,046.88 1,259.79 1,116.34 1,016.47 911.36

Beijing Luzhu Biotechnology Co  (HKSE:02480) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Beijing Luzhu Biotechnology Co's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(911.355-0)/200.989
=4.53

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Beijing Luzhu Biotechnology Co's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.943 + 70.16) / 911.355
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Luzhu Biotechnology Co Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Luzhu Biotechnology Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » Total Stockholders Equity
Comparable Companies
HKSE:02179 HKSE:01541 HKSE:01873 HKSE:01167 HKSE:06660 HKSE:02616 HKSE:06955 HKSE:01477 HKSE:02487 HKSE:02509 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Website
http://www.luzhubiotech.com
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group's product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
Executives
Kong Jian 2101 Beneficial owner
Zhang Yanping 2202 Interest of your spouse
Ma Jianan 2201 Interest of corporation controlled by you
Zhu Hai Heng Qin Lv Zhu Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Bei Jing Lv Zhu Kang Rui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Bei Jing Sai Sheng Yao Ye Gu Fen You Xian Gong Si 2101 Beneficial owner
Bei Jing Yi Zhuang Er Qi Sheng Wu Yi Yao Chan Ye Tou Zi Ji Jin You Xian He Huo 2101 Beneficial owner
Bei Jing Yi Zhuang Sheng Wu Yi Yao Bing Gou Tou Zi Zhong Xin You Xian He Huo 2101 Beneficial owner
Tian Jin Sai Ding Fang De Zi Chan Guan Li Zhong Xin 2201 Interest of corporation controlled by you
Tian Jin Sai De Rui Bo Zi Chan Guan Li Zhong Xin 2201 Interest of corporation controlled by you
Bei Jing Yi Tang Sai Ying Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
China Construction Bank Corporation 2201 Interest of corporation controlled by you
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Peng Ling 2201 Interest of corporation controlled by you
Ma Biao 2201 Interest of corporation controlled by you

Beijing Luzhu Biotechnology Co Headlines

No Headlines